A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a BMI of
* ≥30 kilograms per square meter (kg/m2) or
* ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities:
* Hypertension
* Dyslipidemia
* Cardiovascular disease
* Obstructive sleep apnea
Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
You may not be if
Have a prior or planned surgical treatment for obesity
Have at least one laboratory value suggestive of diabetes during screening
Use of metformin, or any other glucose-lowering medications
Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
Have poorly controlled hypertension
Have any of the following cardiovascular conditions within 3 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure
Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
Have a history of symptomatic gallbladder disease within the past 2 years
Have signs and symptoms of any liver disease
Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
Have a history of acute or chronic pancreatitis
Have renal impairment, measured as estimated glomerular filtration rate \<30 mL/minute/1.73 m2
Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Clareo Health | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
